ISCHEMIC HEART DISEASE

In-Hospital Mortality and Early Preinfarction Angina: a Meta-Analysis of Published Studies

Ignacio Iglesias-Garriz, Carmen Garrote Coloma, Félix Corral Fernández, and Cristina Olalla Gómez

Servicio de Cardiología, Hospital de León, León, Spain.

Introduction and objectives. The occurrence of preinfarction angina (PA) reduces the extent of myocardial necrosis, increases the volume of viable myocardium, and improves left ventricular function. However, there is no agreement about the effect of PA on mortality. The objective of this study was to determine whether PA is associated with in-hospital mortality.

Method. A meta-analysis (fixed effects model) of all published reports evaluating in-hospital mortality in patients with acute myocardial infarction according to the presence or absence of PA was performed. PA was defined as the occurrence of angina in the 24 hours before onset of the infarction. We searched the Medline and Embase databases in June 2004 using "preinfarction angina or prodromal angina and mortality" as search terms. Six studies involving a total of 3497 patients were finally identified.

Results. Only one study reported that PA had a statistically significant beneficial effect on in-hospital mortality. However, combining the data showed that the presence of PA was associated with a significant decrease in the probability of in-hospital death (odds ratio=0.61; 95% CI, 0.48-0.78; *P*<.0001. We did not detect any significant heterogeneity between the studies (χ^2 =5.92; *P*=.31).

Conclusions. The occurrence of preinfarction angina in the 24 hours before the onset of myocardial infarction was associated with a significant reduction in in-hospital mortality of 39%.

Key words: Unstable angina. Myocardial infarction. Prognosis. Meta-analysis.

Mortalidad intrahospitalaria y angina preinfarto temprana: metaanálisis de los estudios publicados

Introducción y objetivos. La presencia de angina preinfarto (AP) reduce el tamaño de la necrosis miocárdica e induce más cantidad de miocardio viable y una mejor función ventricular izquierda. Sin embargo, la asociación entre mortalidad y AP es controvertida. El objetivo de este estudio fue determinar si la AP se asocia con la mortalidad intrahospitalaria.

Método. Se realizó un metaanálisis (modelo de efectos fijos) de los estudios publicados hasta el momento en los que se analiza la mortalidad intrahospitalaria de pacientes con infarto agudo de miocardio según presenten o no AP, definida como la que acontece en las 24 h previas al comienzo del infarto. A partir de las bases de datos MED-LINE y EMBASE se realizó una búsqueda en junio de 2004 con los términos «*preinfarction angina* or *prodromal angina* and *mortality*» y se incluyeron finalmente 6 trabajos, con un total de 3.497 pacientes.

Resultados. En sólo uno de los estudios se encuentra una asociación beneficiosa estadísticamente significativa entre AP y mortalidad intrahospitalaria. Tras agrupar los datos se encontró una reducción significativa en la probabilidad de muerte intrahospitalaria en pacientes con AP (*odds ratio* = 0,61; intervalo de confianza del 95%, 0,48-0,78; p < 0,0001). No se encontró heterogeneidad significativa entre los estudios ($\chi^2 = 5,92$; p = 0,31).

Conclusiones. La presencia de angina en las 24 h previas al inicio del infarto de miocardio se asocia con una reducción significativa de la mortalidad intrahospitalaria del 39%.

Palabras clave: Angina inestable. Infarto de miocardio. Pronóstico. Metaanálisis.

INTRODUCTION

Episodes of angina prior to the onset of acute myocardial infarction can slow the process of cell death.¹ Because of this fact, more cells survive in the myocardial risk area when coronary flow is restored in patients with angina prior to infarction than in those without. Several mechanisms explain this phenomenon: ischemic preconditioning,¹ development of collateral cir-

Correspondence: Dr. I. Iglesias-Garriz. Servicio de Cardiología. Hospital de León. Altos de Nava, s/n. 24071 León. España. E-mail: med016340@saludalia.com

Received September 21, 2004. Accepted for publication February 17, 2005.

ABBREVIATIONS

PA: preinfarction angina. OR: odds ratio.

culation,² and earlier and more effective reperfusion after administration of fibrinolytic treatment or primary angioplasty.³⁻⁵ The most important consequences of preinfarction angina (PA) are a larger volume of viable myocardium⁶ and greater recovery of ventricular function at mid-term following infarction.⁷⁻⁹

There are no conclusive data regarding the association between PA and mortality. Some studies have shown a beneficial association regarding hospital mortality in patients presenting PA,^{4,10-13} at least in the youngest patients,¹³ whereas other studies have demonstrated no benefits¹⁴ or have reported a detrimental effect.¹⁵ Similar results have been found in analyses of middle- and long-term mortality.^{10,14-19} Several factors can explain these differences: a small sample size in most of the series with insufficient statistical power to detect differences, different definitions used for PA, variations in the reperfusion treatment applied in the acute phase, and dissimilar control of confounding variables between the 2 groups.

It is difficult to conduct a large-scale study assessing the association between PA and mortality. It would require a large sample size, which would need coordination among several centers, and a considerable economic investment, which many organizations (e.g., research-funding agencies and the pharmaceutical industry) are not willing to provide. For these reasons, this meta-analysis was designed to assess the influence of PA on in-hospital mortality and evaluate the clinical repercussions derived from the results obtained.

METHOD

Inclusion and Exclusion Criteria

The meta-analysis included published studies that analyzed the relationship between mortality and PA (although this was not their primary objective of analysis). The following studies were excluded: a) those that provided duplicate information (the study offering the most up-to-date information or the largest number of patients was chosen); b) those that did not analyze or did not specifically report total in-hospital mortality; and c) those that did not define PA as an event occurring in the 24 hours before the onset of infarction. If these data were not available in the study and could not be obtained from the principal author, the study was excluded. Acceptance or exclusion of an original study for the analysis was carried out independently by three investigators. In the case of disagreement, the choice was resolved by consensus.

Literature Search

The studies were obtained by searching MEDLINE and EMBASE using the following terms: preinfarction angina or prodromal angina and mortality in the month of June 2004. Initial selection of the studies was made according to title and abstract, and all those apparently not reporting on the research objective were excluded. Three reviewers read the remaining studies independently and analyzed the literature references they contained. The following data were extracted from each of the original studies: design, mean age and number of patients included, percentage of patients treated with fibrinolysis, primary angioplasty or surgery in the acute phase of infarction, percentage of patients who had PA, percentage of patients with a non-Q-wave infarction, and percentage of patients with infarction in an anterior location.

Data Analysis

The main measure of the association was the odds ratio (OR) and 95% confidence interval (CI). The ORs of the individual studies were combined using the fixed effects model according to the method of Mantel-Haenszel.^{20,21} The DerSimonian and Laird²² test was used as the random effects model. Heterogeneity between the studies was assessed with the χ^2 test and the Galbraith plot.²³ Briefly, the Z-statistic (mortality in each study divided by the square root of its variance) was plotted on the y-axis against the inverse of the standard error of each study on the x-axis. An unweighted regression line constrained through the origin was constructed. The studies farthest from this line, which have a standard deviation (SD) of 1, i.e., the outliers, are those that contribute the most to the heterogeneity between the studies. Sensitivity was analyzed to assess the importance of the different statistical models used, the effect of the number of patients treated by reperfusion during the acute phase of infarction, the effect of the study designs, and the influence of each of the original studies. RevMan, version 4.2 (Cochrane Collaboration Oxford, United Kingdom) was used for the statistical analyses. Statistical significance for the effects of treatment and heterogeneity was established at P<.05 and P<.1, respectively.

RESULTS

Results of the Search

The search results are summarized in Figure 1. A total of 55 studies were initially identified as potential




Figure 1. Number of studies assessed for inclusion in the meta-analysis. See more information in the text. PA indicates preinfarction angina.

candidates for inclusion in the meta-analysis. On the basis of the title and abstract, 20 studies were excluded because they did not report on in-hospital mortality and PA. Among the 35 remaining studies, 21 were excluded because of the definition used for PA,^{5,9-15,17,24-35} 6 because they did not analyze in-hospital mortality,^{16,36-40} and 2 because they presented duplicate data.^{4,41} The 6 studies that remained analyzed the influence of PA on in-hospital mortality.^{19,42-46}

Qualitative Findings

Three of the 6 studies ultimately included in the analysis were retrospective^{42,43,46} and the other 3 prospective^{19,44,45} (Table 1). Mean age in the study by Abete et al,⁴⁶ which included patients older than 65 years, was higher than that of patients in the remaining studies. Despite the fact that a uniform definition of PA was used, the study by Abete et al⁴⁶ presented a higher percentage of patients with this symptom (63%) than the remaining studies. In addition, the per-

centage of patients in this study who received reperfusion treatment in the acute phase of infarction was lower (35%) as compared to the others. Two original studies included patients with chronic angina and 5 incorporated patients with a prior history of acute myocardial infarction.^{42-44,46} Two studies contained patients with a diagnosis of non-Q-wave myocardial infarction.^{43,46}

Quantitative Findings

Only 1 of the studies⁴⁴ reported a significantly reduced OR for in-hospital mortality in the group with PA, although the study by Kosuge et al⁴³ showed a clear tendency toward this same association.

When the data were grouped (a total of 3497 patients, 1217 of whom had PA, with 125 deaths in the PA group and 293 in the group without PA), the presence of angina within 24 h before infarction was associated with a significant reduction in the OR for total deaths during in-hospital monitoring (OR=0.61;

	Design	Mean Age, Years	Ν	Percentage of Reperfusion and Method	Percentage of Prior Infarction	Percentage of Preinfarction Angina	Percentage of Non-Q- Wave Infarction
Tamura et al ⁴⁵	Р	61	140	59%, FNL, PCI	51	24	0
Gorecki et al44	Р	66	331	100%, FNL	43	24	0
Kosuge et al ⁴³	R	66	913	100%, PCI	49	39	12
Tomoda et al ⁴²	R	63	613	69%, FNL, PCI	49	27	0
Ishihara et al ¹⁹	Р	61	990	100%, FNL, PCI, CS	51	26	0
Abete et al46	R	73	510	35%, FNL, PCI	-	63	17

*CS indicates coronary surgery; FNL, fibrinolysis; PCI, percutaneous coronary intervention; P, prospective; R, retrospective.

Iglesias-Garriz I, et al. In-Hospital Mortality and Early Preinfarction Angina: a Meta-Analysis of Published Studies

Study and Bibliographic Reference	With Preinfarction Angina, n/N	Without Preinfarction Angina, n/N	Fixed Effects OR, 95% CI	Weight, %	Fixed Effects OR, 95% CI
Tamura et al ⁴⁵	0/34	11/106		3.23	0.12 (0.01-2.10)
Gorecki et al ⁴⁴	8/80	65/251		16.35	0.32 (0.15-0.70)
Kosuge et al ⁴³	10/358	31/555		13.67	0.49 (0.24-1.00)
Tomoda et al ⁴²	14/166	53/447	-	15.20	0.68 (0.37-1.27)
Ishihara et al ¹⁹	21/256	82/734		22.51	0.71 (0.43-1.17)
Abete et al ⁴⁶	72/323	51/187		29.03	0.76 (0.51-1.16)
Total, 95% CI	125/1217	293/2280	•	100.0	0.61 (0.48-0.78)
Heterogeneity Test χ^2 =5.9 Overall Effects Test: Z=3.9	2, gl=5 (<i>P</i> =.31),l2=15.5% /6 (<i>P</i> <.001)				
	· · · ·	I		1	
		0.1	1	10	
		↓ Morta	- т.м	ortality	

Figure 2. Estimation of the association between preinfarction angina and mortality in the individual studies and after their combination.




Figure 3. Galbraith plot.

Ab indicates Abete; Go, Gorecki; Is, Ishihara; Ko, Kosuge; Ta, Tamura; To, Tomoda.

95% CI, 0.48-0.78; *P*<.0001) (Figure 2). No significant differences were found in the heterogeneity test (χ^2 =5.92; *P*=.31). In addition, significant heterogeneity was not seen in the Galbraith plot (Figure 3), which showed no outliers far from the regression line (more than 2 SD).

Sensitivity Analysis

A sensitivity analysis was performed to determine whether the results were consistent (Table 2). First, the analyses performed with the fixed effects method and the random effects method were compared. The 2 models provided a similar estimation of the OR. Second, the studies in which the percentage of patients revascularized in the acute phase was 100% or <100%were analyzed separately. A more beneficial association between PA and mortality in the OR estimation was found when the total of patients was reperfused in the acute phase (0.3 vs 0.0), with both analyses being statistically significant. The influence of the study design (prospective or retrospective) was investigated and in both cases the association was significant, although it was more pronounced for the prospective

TABLE 2. Sensitivity Analysis of the Association
Between Preinfarction Angina and In-Hospital
Mortality

Random effects 6 3497 0.62 (0.46-0.82) Revascularization treatment 1 All patients 3 2234 0.53 (0.37-0.76) Not all patients 3 1263 0.70 (0.50-0.97) Study design 9 1461 0.51 (0.34-0.78)		Number of Studies	Number OR of Patients	for Mortality (95% Cl)
Random effects 6 3497 0.62 (0.46-0.82) Revascularization treatment 1 All patients 3 2234 0.53 (0.37-0.76) Not all patients 3 1263 0.70 (0.50-0.97) Study design 9 9 1461 0.51 (0.34-0.78) Prospective 3 1461 0.51 (0.34-0.78) Retrospective 3 2036 0.68 (0.50-0.92) Analysis when excluding 7 7 7 Tamura et al ⁴⁵ 5 3357 0.62 (0.49-0.80) Gorecki et al ⁴⁴ 5 3166 0.67 (0.51-0.86) Kosuge et al ⁴³ 5 2584 0.63 (0.48-0.82) Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Statistical model			
Revascularization 6 6161 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6162 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6163 6164 6163 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164 6164<	Fixed effects	6	3497	0.61 (0.48-0.78)
treatmentAll patients322340.53 (0.37-0.76)Not all patients312630.70 (0.50-0.97)Study design999Prospective314610.51 (0.34-0.78)Retrospective320360.68 (0.50-0.92)Analysis when excluding7Tamura et al ⁴⁵ 533570.62 (0.49-0.80)Gorecki et al ⁴⁴ 531660.67 (0.51-0.86)Kosuge et al ⁴³ 525840.63 (0.48-0.82)Tomoda et al ⁴² 528840.59 (0.45-0.78)Ishihara et al ¹⁹ 525070.58 (0.44-0.77)	Random effects	6	3497	0.62 (0.46-0.82)
All patients 3 2234 0.53 (0.37-0.76) Not all patients 3 1263 0.70 (0.50-0.97) Study design 9 9 9 9 Prospective 3 1461 0.51 (0.34-0.78) Retrospective 3 2036 0.68 (0.50-0.92) Analysis when excluding 7 7 7 Tamura et al ⁴⁵ 5 3357 0.62 (0.49-0.80) Gorecki et al ⁴⁴ 5 3166 0.67 (0.51-0.86) Kosuge et al ⁴³ 5 2584 0.63 (0.48-0.82) Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Revascularization			
Not all patients 3 1263 0.70 (0.50-0.97) Study design 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 </td <td>treatment</td> <td></td> <td></td> <td></td>	treatment			
Study design314610.51 (0.34-0.78)Prospective320360.68 (0.50-0.92)Analysis when excluding320360.62 (0.49-0.80)Gorecki et al ⁴⁵ 533570.62 (0.49-0.80)Gorecki et al ⁴⁴ 531660.67 (0.51-0.86)Kosuge et al ⁴³ 525840.63 (0.48-0.82)Tomoda et al ⁴² 528840.59 (0.45-0.78)Ishihara et al ¹⁹ 525070.58 (0.44-0.77)	All patients	3	2234	0.53 (0.37-0.76)
$\begin{array}{ccccccc} \mbox{Prospective} & 3 & 1461 & 0.51 & (0.34-0.78) \\ \mbox{Retrospective} & 3 & 2036 & 0.68 & (0.50-0.92) \\ \mbox{Analysis when excluding} \\ \mbox{Tamura et al}^{45} & 5 & 3357 & 0.62 & (0.49-0.80) \\ \mbox{Gorecki et al}^{44} & 5 & 3166 & 0.67 & (0.51-0.86) \\ \mbox{Kosuge et al}^{43} & 5 & 2584 & 0.63 & (0.48-0.82) \\ \mbox{Tomoda et al}^{42} & 5 & 2884 & 0.59 & (0.45-0.78) \\ \mbox{Ishihara et al}^{19} & 5 & 2507 & 0.58 & (0.44-0.77) \\ \end{array}$	Not all patients	3	1263	0.70 (0.50-0.97)
Retrospective 3 2036 0.68 (0.50-0.92) Analysis when excluding - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -	Study design			
Analysis when excludingTamura et al45533570.62 (0.49-0.80)Gorecki et al44531660.67 (0.51-0.86)Kosuge et al43525840.63 (0.48-0.82)Tomoda et al42528840.59 (0.45-0.78)Ishihara et al19525070.58 (0.44-0.77)	Prospective	3	1461	0.51 (0.34-0.78)
Tamura et al ⁴⁵ 5 3357 0.62 (0.49-0.80) Gorecki et al ⁴⁴ 5 3166 0.67 (0.51-0.86) Kosuge et al ⁴³ 5 2584 0.63 (0.48-0.82) Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Retrospective	3	2036	0.68 (0.50-0.92)
Gorecki et al ⁴⁴ 5 3166 0.67 (0.51-0.86) Kosuge et al ⁴³ 5 2584 0.63 (0.48-0.82) Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Analysis when excluding			
Kosuge et al ⁴³ 5 2584 0.63 (0.48-0.82) Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Tamura et al45	5	3357	0.62 (0.49-0.80)
Tomoda et al ⁴² 5 2884 0.59 (0.45-0.78) Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Gorecki et al44	5	3166	0.67 (0.51-0.86)
Ishihara et al ¹⁹ 5 2507 0.58 (0.44-0.77)	Kosuge et al43	5	2584	0.63 (0.48-0.82)
	Tomoda et al42	5	2884	0.59 (0.45-0.78)
Abete et al ⁴⁶ 5 2987 0.54 (0.40-0.74)	Ishihara et al ¹⁹	5	2507	0.58 (0.44-0.77)
	Abete et al46	5	2987	0.54 (0.40-0.74)

*OR indicates odds ratio.

studies (0.51 vs 0.68). Lastly, to assess the influence of the individual studies, each study was excluded from the analysis one by one. The OR values varied from 0.54 to 0.67 after exclusion of the original studies in this manner. None of the studies showed a decisive impact on the overall OR estimation.

DISCUSSION

The results of this study showed a significant reduction in in-hospital mortality in patients with acute myocardial infarction, the majority reperfused in the acute phase, if they had presented episodes of angina within the 24 hours prior to the onset of infarction.

Previous studies have reported that PA has a beneficial clinical effect, including preservation of left ventricular function, a lower probability of heart failure,^{11,26} and a reduction in the susceptibility to present ventricular arrhythmia.36,45 There are several mechanisms by which PA exerts these marked benefits. Probably the most important is a biphasic biochemical phenomenon known as ischemic preconditioning. Recent studies on this phenomenon have implicated transient mitochondrial permeability transition pore (mPTP) opening, which could have the ATPase-dependent potassium channel as a component.⁴⁷ Another mechanism is the development of collateral circulation from the non-ischemic areas. In 2 of the studies included in the meta-analysis,9,42 the presence of collateral circulation was assessed by the method of Rentrop et al,48 with no significant differences observed between the 2 groups. It is likely that the short evolution time for angina prior to infarction defined in the present study as an inclusion criterion did not allow the development of macroscopic collateral circulation. Only 2 of the studies analyzed included cases of chronic angina,44,46 with a total of 284 patients (8% of all patients in the meta-analysis); thus, considerable development of collateral circulation may not be the definitive explanation for the results of the meta-analysis. Another proposed mechanism for the benefits of PA is better and more stable reperfusion with fibrinolytic treatment³ or primary angioplasty.^{4,5} In the meta-analysis, the majority of patients received revascularization treatment in the acute stage of infarction (overall, 82% of the patients included); hence this could be an important factor to explain the results found. This mechanism seems even more relevant considering the sensitivity analysis, in which the association with mortality was more pronounced when only the studies with 100% reperfusion were included. Another benefit of PA has been attributed to reductions in microvascular injury⁵ and reperfusion injury,⁴⁹ although these factors have not been investigated in depth. Moreover, an association has been described between PA and spontaneous recanalization of the artery causing the infarction, a fact that can contribute to the clinical benefits observed by facilitating

earlier perfusion.⁵⁰ Lastly, the beneficial association between PA and mortality may be related to differing pharmacological treatment between the 2 groups before the onset of infarction. This hypothesis also requires further investigation.

The meta-analysis included patients with diabetes, patients treated with percutaneous revascularization in the acute phase, and elderly patients; in one study only patients 65 years and older participated.⁴⁶ There are some doubts as to the benefits of PA in these 3 groups.^{25,41,42,51,52} It is unknown whether the decrease in mortality might be even higher in patient populations outside of these groups, and further specific analyses investigating this hypothesis would be desirable. This consideration is important when interpreting the results of the present study, since 26% of the patients analyzed had diabetes and 54% (1884 patients) underwent percutaneous revascularization in the acute phase (65% of all patients with acute-phase reperfusion). It is possible that the association between PA and mortality might be stronger in the group of non-diabetic patients treated with intravenous fibrinolysis. The clinical benefits of PA in patients with primary angioplasty is under discussion,^{9,25} although an association has been described between the presence of PA and the probability of complete epicardial recanalization of the culprit artery during the procedure⁴ (this fact is important considering that 5 of the 6 studies included in the meta-analysis used this revascularization method in the acute phase). Nevertheless, the design of the studies and the number of patients included raise doubts as to the validity of the results. One prospective study by our group done in patients with elevated ST segment myocardial infarction undergoing primary angioplasty in the acute phase showed a significant reduction in the size of the infarct measured by ^{99m}Tc-sestamibi scintigraphy in those presenting PA (data accepted for publication). Therefore, it cannot be ruled out that the benefits of PA are also maintained in patients treated with primary angioplasty.

The results of this study raise the question as to whether a prospective study including a large number of patients is necessary to analyze the influence of PA in the prognosis. It is known that agreement for the direction of the effect between the results of a metaanalysis and those of large-scale studies analyzing a similar effect and performed after the meta-analysis is approximately 80%.⁵³ Therefore, it is very probable that the direction of the association of PA is toward a reduction in mortality, even though only one original study suggested a significant association in this regard.

Limitations of the Study

Potential publication bias should be taken into account when interpreting the results of this study. Attempts were made to avoid publication bias by performing a comprehensive review of the subject and analyzing the funnel plot, in which asymmetry in the distribution of the studies was found. Nevertheless, the usefulness of the funnel plot is likely to be limited by the small number of studies included in the metaanalysis. The fact that only published studies were included may have induced bias in the selection of candidate studies to be incorporated. Relevant information that has not been published in scientific journals may have been excluded from the study.

The compiling of individual studies with differing designs and criteria for exclusion and inclusion gives the sample an appearance of heterogeneity. Nonetheless, significant heterogeneity was not detected and the sensitivity analysis showed a relationship between PA and mortality that was similar and in the same direction in all cases. However, the dissimilar characteristics of the patients included in the individual studies should be taken into account in the interpretation of the results; in two studies^{43,46} patients with non-ST segment elevation myocardial infarction were incorporated and there was considerable variation in the use of reperfusion treatment in the acute phase. These 2 factors are important if we take into account that the benefit of PA should be limited to the group of patients in whom prolonged ischemia is interrupted by acute-phase revascularization treatment. Although it would have been desirable to estimate the quality of the studies for their subsequent analysis, this was not done because of the small number of studies ultimately included.

CONCLUSIONS

The presence of PA was associated with a significant reduction in in-hospital mortality. Several mechanisms could be responsible for this beneficial association. It would be desirable to conduct a large-scale study to determine the precise magnitude of this benefit as well as its pathophysiological mechanisms, particularly in patients with fibrinolytic treatment or primary percutaneous revascularization, since these seem to be the ones that obtain the greatest benefits.

REFERENCES

- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-36.
- Billinger M, Fleisch M, Eberli FR, Garachemani A, Meier B, Seiler C. Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol. 1999;33:1027-35.
- Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med. 1996;334:7-12.

- Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997;30:970-5.
- Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, et al. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J. 2002;144:796-803.
- Iglesias-Garriz I, Corral F, Rodríguez MA, Garrote C, Montes M, Sevillano E. Pre-infarction angina elicits greater myocardial viability on reperfusion after myocardial infarction: a dobutamine stress echocardiographic study. J Am Coll Cardiol. 2001;37: 1846-50.
- Iglesias-Garriz I, Rodríguez MA, Garrote C, Corral F, Pascual C. Effect of preexisting angina pectoris on left ventricular function following acute myocardial infarction treated with thrombolysis or coronary angioplasty. Am J Cardiol. 2002;90:781-3.
- Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, et al. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of «preconditioning». J Am Coll Cardiol. 1995;25:1076-83.
- Noda T, Minatoguchi S, Fujii K, Hori M, Ito T, Kanmatsuse K, et al. Evidence for the delayed effect in human ischemic preconditioning: prospective multicenter study for preconditioning in acute myocardial infarction. J Am Coll Cardiol. 1999;34:1966-74.
- Muller DW, Topol EJ, Califf RM, Sigmon KN, Gorman L, George BS, et al. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J. 1990;119:224-31.
- Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995;91:37-45.
- Anzai T, Yoshikawa T, Asakura Y, Abe S, Meguro T, Akaishi M, et al. Effect on short-term prognosis and left ventricular function of angina pectoris prior to first Q-wave anterior wall acute myocardial infarction. Am J Cardiol. 1994;74:755-9.
- 13. Abete P, Ferrara N, Cacciatore F, Madrid A, Bianco S, Calabrese C, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol. 1997;30:947-54.
- Pierard LA, Dubois C, Smeets JP, Boland J, Carlier J, Kulbertus HE. Prognostic significance of angina pectoris before first acute myocardial infarction. Am J Cardiol. 1988;61:984-7.
- Behar S, Reicher-Reiss H, Abinader E, Agmon J, Friedman Y, Barzilai J, et al. The prognostic significance of angina pectoris preceding the occurrence of a first acute myocardial infarction in 4166 consecutive hospitalized patients. Am Heart J. 1992;123: 1481-6.
- Iglesias-Garriz I, Sastre M, Delgado S, Garrote C, Corral F, Montes M, et al. Influencia de la angina preinfarto en la mortalidad a medio plazo tras infarto agudo de miocardio. Rev Esp Cardiol. 2000;53:1329-34.
- Ruocco NA Jr, Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ. Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). J Am Coll Cardiol. 1992;20:1445-51.
- Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993;125:863-72.
- Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Ueda K, et al. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. Am Heart J. 2000;139:881-8.
- Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986;124:719-23.
- Mantel H, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22: 719-48.

Iglesias-Garriz I, et al. In-Hospital Mortality and Early Preinfarction Angina: a Meta-Analysis of Published Studies

 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.

23. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-94.

- Kobayashi Y, Miyazaki S, Miyao Y, Morii I, Matsumoto T, Daikoku S, et al. Effect on survival of previous angina pectoris after acute myocardial infarction. Am J Cardiol. 1997;79:1534-8.
- 25. Zahn R, Schiele R, Schneider S, Gitt AK, Seidl K, Bossaller C, et al. Effect of preinfarction angina pectoris on outcome in patients with acute myocardial infarction treated with primary angioplasty (results from the Myocardial Infarction Registry). Am J Cardiol. 2001;87:1-6.
- 26. Jiménez-Navarro M, Gómez-Doblas JJ, Alonso-Briales J, Hernández García JM, Gómez G, Alcántara AG, et al. Does angina the week before protect against first myocardial infarction in elderly patients? Am J Cardiol. 2001;87:11-5.
- Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation. 1995;91:291-7.
- Shiraki H, Yoshikawa T, Anzai T, Negishi K, Takahashi T, Asakura Y, et al. Association between preinfarction angina and a lower risk of right ventricular infarction. N Engl J Med. 1998; 338:941-7.
- 29. Harper RW, Kennedy G, DeSanctis RW, Hutter AM Jr. The incidence and pattern of angina prior to acute myocardial infarction: a study of 577 cases. Am Heart J. 1979;97:178-83.
- 30. Barbash GI, White HD, Modan M, van de Werf F. Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol. 1992;20:36-41.
- 31. Anzai T, Yoshikawa T, Asakura Y, Abe S, Akaishi M, Mitamura H, et al. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarction. J Am Coll Cardiol. 1995;26:319-27.
- Neskovic AN, Pavlovski K, Bojic D, Popovic Z, Otasevic P, Vlahovic A, et al. Preinfarction angina prevents left ventricular remodeling in patients treated with thrombolysis for myocardial infarction. Clin Cardiol. 2001;24:364-70.
- Liuzzo G, Baisucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol. 1999; 34:1696-703.
- Gundersen T, Kjekshus J. The importance of pre- and postinfarction angina on timolol-related reduction in mortality and reinfarction. Clin Cardiol. 1985;8:87-92.
- Jiménez-Navarro M, Gómez-Doblas J, Gómez G, García AA, Hernández JM, Alonso BJ, et al. Influencia de la angina en la semana previa al primer infarto de miocardio. Rev Esp Cardiol. 2001;54:1161-6.
- 36. Gheeraert PJ, Henriques JP, de Buyzere ML, de Pauw M, Taeymans Y, Zijlstra F. Preinfarction angina protects against out-ofhospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol. 2001;38:1369-74.
- Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998;97:1042-5.
- 38. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Effect of prodromal angina pectoris on altering the relation

between time to reperfusion and outcomes after a first anterior wall acute myocardial infarction. Am J Cardiol. 2003;91: 128-32.

- 39. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Effect of acute hyperglycemia on the ischemic preconditioning effect of prodromal angina pectoris in patients with a first anterior wall acute myocardial infarction. Am J Cardiol. 2003;92:288-91.
- Lamfers EJ, Hooghoudt TE, Hertzberger DP, Schut A, Stolwijk PW, Verheugt FW. Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients' characteristics, and prognosis. Heart. 2003;89:496-501.
- Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol. 2001;38:1007-11.
- 42. Tomoda H, Aoki N. Comparison of protective effects of preinfarction angina pectoris in acute myocardial infarction treated by thrombolysis versus by primary coronary angioplasty with stenting. Am J Cardiol. 1999;84:621-5.
- 43. Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Effects of preinfarction angina pectoris on infarct size and in-hospital mortality after coronary intervention for acute myocardial infarction. Am J Cardiol. 2003;92:840-3.
- Gorecki A, Chamiec T, Bednarz B, Maciejewski P, Lukaszewicz R, Ceremuzynski L. Is preinfarction angina associated with better outcome after myocardial infarction? Kardiol Pol. 2003;58:457-68.
- 45. Tamura K, Tsuji H, Nishiue T, Tokunaga S, Iwasaka T. Association of preceding angina with in-hospital life-threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Am Heart J. 1997;133:297-301.
- 46. Abete P, Ferrara N, Cacciatore F, Sagnelli E, Manzi M, Carnovale V, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol. 2001;38:1357-65.
- Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation. 2004;109:1714-7.
- Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92.
- 49. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, et al. Effect of preinfarction angina pectoris on ST-segment resolution after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2002;90:465-9.
- Lee CW, Hong MK, Lee JH, Yang HS, Kim JJ, Park SW, et al. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am J Cardiol. 2001;87:951-4.
- Lee TM, Su SF, Chou TF, Lee YT, Tsai CH. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation. 2002;105:334-40.
- 52. Tomai F, Danesi A, Ghini AS, Crea F, Perino M, Gaspardone A, et al. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J. 1999;20:196-202.
- LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536-42.